Tryptamine Therapeutics Ltd
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 … Read more
Tryptamine Therapeutics Ltd (TYP) - Net Assets
Latest net assets as of December 2023: AU$2.71 Million AUD
Based on the latest financial reports, Tryptamine Therapeutics Ltd (TYP) has net assets worth AU$2.71 Million AUD as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$3.08 Million) and total liabilities (AU$367.88K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$2.71 Million |
| % of Total Assets | 88.07% |
| Annual Growth Rate | -10.34% |
| 5-Year Change | -19.39% |
| 10-Year Change | N/A |
| Growth Volatility | 125.51 |
Tryptamine Therapeutics Ltd - Net Assets Trend (2018–2023)
This chart illustrates how Tryptamine Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tryptamine Therapeutics Ltd (2018–2023)
The table below shows the annual net assets of Tryptamine Therapeutics Ltd from 2018 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-06-30 | AU$4.13 Million | -53.14% |
| 2022-06-30 | AU$8.81 Million | -53.32% |
| 2021-06-30 | AU$18.87 Million | +276.03% |
| 2020-06-30 | AU$5.02 Million | -2.00% |
| 2019-06-30 | AU$5.12 Million | -28.13% |
| 2018-06-30 | AU$7.12 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tryptamine Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3341967200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$36.73 Million | 889.89% |
| Other Comprehensive Income | AU$822.33K | 19.93% |
| Total Equity | AU$4.13 Million | 100.00% |
Tryptamine Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Tryptamine Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Safe Fertility Group Public Company Limited
BK:SAFE
|
$19.84 Million |
|
Fitzroy Minerals Inc
OTCQB:FTZFF
|
$19.85 Million |
|
Force MOS Technology Co., LTD.
TWO:4923
|
$19.85 Million |
|
FARMAE S.P.A.
F:U5Y
|
$19.85 Million |
|
Lippo Malls Indonesia Retail Trust
PINK:LPMDF
|
$19.83 Million |
|
Mico BioMed Co. Ltd.
KQ:214610
|
$19.82 Million |
|
Wisr Ltd
AU:WZR
|
$19.82 Million |
|
Sýn hf
IC:SYN
|
$19.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tryptamine Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 8,807,758 to 4,126,943, a change of -4,680,815 (-53.1%).
- Net loss of 7,130,264 reduced equity.
- New share issuances of 1,572,115 increased equity.
- Other comprehensive income increased equity by 37,700.
- Other factors increased equity by 839,634.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-7.13 Million | -172.77% |
| Share Issuances | AU$1.57 Million | +38.09% |
| Other Comprehensive Income | AU$37.70K | +0.91% |
| Other Changes | AU$839.63K | +20.35% |
| Total Change | AU$- | -53.14% |
Book Value vs Market Value Analysis
This analysis compares Tryptamine Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.62x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 68.00x to 1.62x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-06-30 | AU$0.00 | AU$0.03 | x |
| 2016-06-30 | AU$0.00 | AU$0.03 | x |
| 2017-06-30 | AU$0.00 | AU$0.03 | x |
| 2018-06-30 | AU$0.08 | AU$0.03 | x |
| 2019-06-30 | AU$0.08 | AU$0.03 | x |
| 2020-06-30 | AU$0.05 | AU$0.03 | x |
| 2021-06-30 | AU$0.13 | AU$0.03 | x |
| 2022-06-30 | AU$0.05 | AU$0.03 | x |
| 2023-06-30 | AU$0.02 | AU$0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tryptamine Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -172.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1152.70%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 1.43x
- Recent ROE (-172.77%) is below the historical average (-106.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -472.00% | 0.00% | 0.00x | 1.00x | AU$-241.00 |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | AU$-226.40 |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | AU$-488.90 |
| 2018 | -2.45% | -397.54% | 0.01x | 1.01x | AU$-886.98K |
| 2019 | -42.86% | 0.00% | 0.00x | 1.05x | AU$-2.71 Million |
| 2020 | -104.00% | -199.51% | 0.40x | 1.30x | AU$-5.72 Million |
| 2021 | -44.85% | -201.85% | 0.20x | 1.14x | AU$-10.35 Million |
| 2022 | -115.41% | -10192.76% | 0.01x | 1.55x | AU$-11.05 Million |
| 2023 | -172.77% | -1152.70% | 0.11x | 1.43x | AU$-7.54 Million |
Industry Comparison
This section compares Tryptamine Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $31,815,679
- Average return on equity (ROE) among peers: -60.84%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tryptamine Therapeutics Ltd (TYP) | AU$2.71 Million | -472.00% | 0.14x | $19.83 Million |
| Adalta Ltd (1AD) | $2.03 Million | -265.03% | 1.74x | $171.91K |
| Algorae Pharmaceuticals Ltd (1AI) | $2.88 Million | -33.65% | 0.18x | $9.99 Million |
| ACRUX Ltd (ACR) | $17.49 Million | -17.99% | 0.05x | $2.16 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $11.42 Million |
| Arovella Therapeutics Ltd (ALA) | $11.23 Million | -77.89% | 0.18x | $39.76 Million |
| Anatara Lifesciences Ltd (ANR) | $5.92 Million | -48.49% | 0.08x | $718.75K |
| Bio-Gene Technology Ltd (BGT) | $4.25 Million | -56.43% | 0.18x | $2.33 Million |
| BTC Health Ltd (BTC) | $11.34 Million | -4.81% | 0.03x | $364.22 |
| Cambium Bio Ltd (CMB) | $8.27 Million | -79.86% | 0.16x | $8.11 Million |
| Clinuvel Pharmaceuticals Ltd (CUV) | $240.81 Million | 15.02% | 0.13x | $251.65 Million |